Онкология 조장호 Favorite Doctor
- SpecialtyLung cancer, esophageal cancer, head & neck cancer, stomach cancer
- Site
Schedule
| Week | M | T | W | T | F | S |
|---|---|---|---|---|---|---|
| AM | Present | |||||
| PM | Present | Present |
Clinical Interests
Education
Career
Community
Training
License
Paper
| Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol. 2020 Feb 10;38(5):488-495 | |
| Cho JH, Lim JY, Choi AR, Choi SM, Kim JW, Choi SH, Cho JY, Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor, Cancer Res Treat. 2015 Oct;47(4):697-705 | |
| Cho JH, Lim JY, Cho JY. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer. World J Gastroenterol 2017; 23(41): 7407-7414 | |
| Cho JH, Lim JY, Cho JY. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. PloS one. 2017;12(10):e0186362 | |
| Cho JH, Ku BM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018;13(3):e29-e31 | |
| Cho JH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018;13(3):e34-e6 | |
| Cho JH, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. J Cancer Res Clin Oncol. 2019 May;145(5):1341-1349 | |
| Cho JH, Kim JS, Kim ST, Hong JY, Park JO, Park YS, Nam DH, Lee DW, Lee J. Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system. PLoS One. 2019 Apr 17;14(4):e0215080 | |
| Cho JH, Kim SY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST. Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs. Transl Cancer Res 2019;8(5):2107-2112 | |
| Cho JH, Shim JH, Yoon SE, Kim HJ, Kim SH, Ko YH, Lee ST, Kim K, Kim WS, Kim SJ, Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia. Korean J Intern Med. 2021 May;36(3):668-678 | |
| Cho JH, Sim MH, Kim SY, Kim K, Lee T, Lee J, Kang WK, Kim ST. Analysis of intrapatient heterogeneity of circulating tumor cells at the single-cell level in the cerebrospinal fluid of a patient with metastatic gastric cancer. J Cancer Res Ther. 2021 Jul-Sep;17(4):1047-1051. | |
| Lim JY, Cho JH, Lee SJ, Lee DK, Yoon DS, Cho JY. Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer, Cancer Res Treat. 2015 Apr;47(2):266-73 | |
| Park SE, Noh JM, Kim YJ, Lee HS, Cho JH, Lim SW, Ahn YC, Pyo H, Choi YL, Han J, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. EGFR Mutation is Associated with Short Progression Free Survival in Patients with Stage III Non-Squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. Cancer Res Treat. 2019 Apr;51(2):493-501 | |
| Byeon S, Kim Y, Lim SW, Cho JH, Park S, Lee J, Sun JM, Choi YL, Lee SH, Ahn JS, Park K, Ahn MJ. Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. Cancer Res Treat. 2019 Apr;51(2):623-631. | |
| Kim HK, Park KH, Kim Y, Park SE, Lee HS, Lim SW, Cho JH, Kim JY, Lee JE, Ahn JS, Im YH, Yu JH, Park YH. Discordance of the PAM50 Intrinsic Subtypes Compared with IHC-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance. Cancer Res Treat. 2019 Apr;51(2):737-747 | |
| Lim SW, Park S, Kim Y, Cho JH, Park SE, Lee H, Kim HK, Kim SM, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial. Lung Cancer. 2018 Oct; 124:293-297 | |
| Kim HK, Lee SH, Kim YJ, Park SE, Lee HS, Lim SW, Cho JH, Kim JY, Ahn JS, Im YH, Yu JH, Park YH. Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea. BMC Cancer. 2019 Jan 17;19(1):84. | |
| Hong J, Kim Y, Cho J, Lim SW, Park SE, Kim HK, Lee H, Cho SY, Kim JY, Ahn JS, Im YH, Park YH. Clinical features and prognosis of breast cancer with gastric metastasis. Oncol Lett. 2019 Feb;17(2):1833-1841 | |
| Yoon SE, Kim Y, Cho J, Kang M, Sung HH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Choi HY, Lee SJ, Park SH. A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naive prostate cancer. BMC Urol. 2019 May 3;19(1):30 | |
| Byeon S, Cho JH, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. Cancer Med 2020 Apr;9(7):2352-2362. | |
| Chang H, Lee YG, Ko YH, Cho JH, Choi JK, Park KU, Kang EJ, Lee KW, Lim SM, Kim JS, Lee HW, Kim MK, Hwang IG, Kim S, Nam BH, Kim HR. Prognostic value of CD200R1 mRNA expression in head and neck squamous cell carcinoma. Cancers (Basel). 2020 Jul 3;12(7):1777 | |
| Choi YJ, Choi JY, Kim JW, Lim AR, Lee Y, Chang WJ, Lee S, Sung JS, Chung HJ, Lee JW, Kang EJ, Kim JS, Lim T, Kim HS, Kim YJ, Ahn MS, Kim YS, Park JH, Lim S, Cho SS, Cho JH, Shin SW, Park KH, Kim YH. Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with that of Orthogonal Methods for Detecting Targetable Genetic Alterations. Cancer Res Treat. 2022 Jan;54(1):30-39 | |
| Kim H, Kim DW, Kim M, Lee Y, Ahn HK, Cho JH, Kim IH, Lee YG, Shin SH, Park SE, Jung J, Kang EJ, Ahn MJ. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11). Cancer. 2022 Feb 15;128(4):778-787 | |
| Kim KH, Yoon S, Ahn HK, Lee SY, Lee GW, Lee SS, Cho JH, Cho BC, Yoon HI, Lim SM. A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11). Clin Lung Cancer. 2022 Aug 7:S1525-7304(22)00169-3 | |
| Lim SH, Lee KW, Kim JJ, Im HS, Kim IH, Han HS, Koo DH, Cho JH, Maeng CH, Lee MY, Lee HJ, Kim JH, Park SG, Jung JY, Shin SH, Kim KH, Kim H, Oh SY, Kang M, Jung M, Rha SY. Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06). BMC Cancer. 2024 Feb 23;24(1):252. doi: 10.1186/s12885-024-11972-w | |
| Cho JH. A New Chemotherapy Paradigm in Advanced Esophageal Cancer. Journal of Digestive Cancer Research 2022; 10(1): 43-45 | |
| Cho JH, Kwon GY, Kang M, Sung HH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Choi HY, Lee SJ, Park SH. Node-positive bladder cancer after neoadjuvant chemotherapy followed by radical cystectomy: A single-center retrospective study. Korean J Urol Oncol 2020;18(3):194-200 | |
| Cho JH, Lee J, Anti-programmed death ligand 1 (PD-L1) inhibitors in metastatic gastric cancer, Precis Future Med. 2017;1(4):152-158. ESCI | |
| Cho JH, Kim SH, Kim YU, Park HS, Cho ES, Lim JY, Cho JY. A case of adenocarcinomatous transformation of a sacrococcygeal teratoma in an adult. Korean J Med. 2013;85(1):101-105. | |
| . Chun YJ, Choi AR, Yang SY, Kim HE, Cho JH, Lim JY, Cho JY. Treatment of a patient with kaposi’s sarcoma arising during hemodialysis with the multikinase inhibitor pazopanib. Korean J Med. 2015;89(1):113-116 | |
| Cha JJ, Kyung CH, Cho JH, Kim YH, Kim HW, Lee SJ, Rim SJ, Choi EY. Severe Mitral Regurgitation Due to Coronary Vasospasm, Confirmed by Ergonovine Echocardiography. Yeungnam Univ J Med. 2013 Dec;30(2):120-123 | |
| Ko HS, Choi AR, Kim TH, Kyung CH, Cho JH, Kim YH, Lee JE. A Case of Continuous Ambulatory Peritonitis Dialysis Peritonitis Due to Stenotrophomonas maltophilia Using Antibiotic Combination. Yeungnam Univ J Med. 2013 Dec;30(2):109-111. | |
| Kim S, Kyung C, Kim YH, Cho JH, Hwang C, Lee JE. Furosemide induced medullary nephrocalcinosis mimicking Bartter syndrome. Yeungnam Univ J Med. 2014 Jun;31(1):21-24. |
